A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1SELECTED NONSMALL CELL LUNG CANCER.

F. HOFFMANN-LA ROCHE LTD.,0 个研究点目标入组 6 人开始时间: 2020年3月9日最近更新: 2024年8月20日

适应症

试验速览

阶段: 未知
状态: 招募中
发起方: F. HOFFMANN-LA ROCHE LTD.,
入组人数: 6

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•Signed Informed Consent Form
•Age 18 years at time of signing Informed Consent Form
•Ability to comply with the study protocol, in the investigator´s judgment
•ECOG Performance Status of 0 or 1
•Histologically or cytologically documented locally advanced or recurrent NSCLC that is not
•eligible for curative surgery and/or definitive chemoradiotherapy, or metastatic Stage IV
•No prior systemic treatment for metastatic NSCLC
•Patients who received prior neo-adjuvant, adjuvant chemotherapy, and/or
•chemoradiotherapy with curative intent for non-metastatic disease are eligible for the
•study if the therapy was completed at least 6 months prior to initiation of study treatment.
•Tumor PD-L1 expression with a TPS 50%, as determined by the PD-L1 IHC 22C3
•pharmDx assay and documented through central testing of a representative tumor tissue, in
•either a previously obtained archival tumor tissue or tissue obtained from a biopsy at
•Measurable disease per RECIST v1.1
•Life expectancy 12 weeks
•Adequate hematologic and end-organ function, defined by the following laboratory test
•For patients receiving therapeutic anticoagulation: stable anticoagulant regimen
•Negative HIV test at screening
•Negative hepatitis B surface antigen (HBsAg) test at screening
•See protocol for more detail.

排除标准

•NSCLC known to have a mutation in the EGFR gene or an ALK fusion oncogene are
•excluded from the study.
•Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
•Spinal cord compression not definitively treated with surgery and/or radiation, and/or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for  2 weeks prior to screening
•History of leptomeningeal disease
•Uncontrolled tumor-related pain
•Patients requiring pain medication must be on a stable regimen at study entry.
•Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period.
•Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment.
•Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently).
•Patients with indwelling catheters (e.g., PleurX®) are allowed regardless of drainage frequency.
•Uncontrolled or symptomatic hypercalcemia (ionized calcium  1.5 mmol/L, calcium  12 mg/dL, or corrected calcium greater than ULN)
•Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barre syndrome, or multiple sclerosis.
•History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
•History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
•Active tuberculosis
•Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease, or current alcohol abuse.
•Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
•See protocol for more detail.

研究者

发起方

F. HOFFMANN-LA ROCHE LTD.,

相似试验

进行中（未招募）

1 期

A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer.on-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-002925-31-ESF. Hoffmann-La Roche Ltd500

进行中（未招募）

1 期

EUCTR2019-002925-31-GRF. Hoffmann-La Roche Ltd560

进行中（未招募）

1 期

A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an Anti-PD-L1 Antibody) in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer.on-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-002925-31-NLF. Hoffmann-La Roche Ltd560

进行中（未招募）

1 期

EUCTR2019-002925-31-DKF. Hoffmann-La Roche Ltd560

进行中（未招募）

1 期

EUCTR2019-002925-31-HUF. Hoffmann-La Roche Ltd560